##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 7 (2025)

Coronavirus infection and chronic lung allograft dysfunction: a retrospective cohort study

Cite this as:
Swiss Med Wkly. 2025;155:3568
Published
08.07.2025

Summary

INTRODUCTION: Long-term survival in lung transplant recipients is limited by chronic lung allograft dysfunction, which can be triggered by respiratory tract infections.

STUDY AIMS: We investigated the incidence of chronic lung allograft dysfunction in a cohort of lung transplant recipients over 10 years, focusing on its association with human coronavirus (HCoV) respiratory tract infections and all-cause mortality.

METHODS: This 10-year retrospective cohort included 259 lung transplant recipients between 2010 and 2020. Nasopharyngeal swab samples were analysed during regular outpatient visits and when symptoms indicated respiratory tract infections using a multiplex polymerase chain reaction panel to test for HCoV subtypes 229E, HKU1, NL63, and OC43. Data regarding chronic lung allograft dysfunction, clinical characteristics, infectious parameters, and lung function tests were recorded. An adjusted Cox proportional hazards regression model was applied.

RESULTS: 166 lung transplant recipients survived the early postoperative period. Over a cumulative observation period of 711.4 patient-years, 57.8% (96/166) of patients were confirmed to have had at least one HCoV infection. On average, the incidence of HCoV respiratory tract infections (n = 380) was 0.53±0.33 per patient-year, and 32.9% (125/380) of respiratory tract infections were in asymptomatic patients. In routine follow-up visits, patients were tested for HCoV infections based on unclear inflammatory responses. Chronic lung allograft dysfunction developed in 45.8% (76/166) of lung transplant recipients. HCoV infections were associated with a higher subsequent likelihood of chronic lung allograft dysfunction (hazard ratio [HR] adjusted = 2.52, 95% CI 1.32–4.80, p = 0.005). After contracting HCoV infections, lung transplant recipients experienced higher C-reactive protein levels on days 4 and 5 after the infection, but there were no immediate changes in lung function parameters.

CONCLUSION: While HCoV infections may not always show symptoms, they may increase the likelihood of subsequent chronic lung allograft dysfunction in lung transplant recipients.

References

  1. Scheffert JL, Raza K. Immunosuppression in lung transplantation. J Thorac Dis. 2014 Aug;6(8):1039–53.
  2. Thabut G, Mal H. Outcomes after lung transplantation. J Thorac Dis. 2017 Aug;9(8):2684–91. doi: https://doi.org/10.21037/jtd.2017.07.85
  3. Schuurmans MM, Benden C, Huber LC. Managing viral respiratory tract infections in lung transplant recipients. Eurasian J Pulmonol. 2015;16(3):144–9. doi: https://doi.org/10.5152/ejp.2014.87597
  4. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007 Dec;357(25):2601–14. doi: https://doi.org/10.1056/NEJMra064928
  5. Shalhoub S, Husain S. Community-acquired respiratory viral infections in lung transplant recipients. Curr Opin Infect Dis. 2013 Aug;26(4):302–8. doi: https://doi.org/10.1097/QCO.0b013e3283630e85
  6. Vu DL, Bridevaux PO, Aubert JD, Soccal PM, Kaiser L. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant. 2011 May;11(5):1071–8. doi: https://doi.org/10.1111/j.1600-6143.2011.03490.x
  7. Verleden GM, Glanville AR, Lease ED, Fisher AJ, Calabrese F, Corris PA, et al. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019 May;38(5):493–503. doi: https://doi.org/10.1016/j.healun.2019.03.009
  8. Byrne D, Nador RG, English JC, Yee J, Levy R, Bergeron C, et al. Chronic lung allograft dysfunction: review of CT and pathologic findings. Radiol Cardiothorac Imaging. 2021 Feb;3(1):e200314. doi: https://doi.org/10.1148/ryct.2021200314
  9. Liu DX, Liang JQ, Fung TS. Human Coronavirus-229E, -OC43, -NL63, and - HKU1 (Coronaviridae). Encycl Virol. 2020;1-5:428–40. 10.1016/B978-0- 12-809633-8.21501-X doi: https://doi.org/10.1016/B978-0-12-809633-8.21501-X
  10. Munting A, Manuel O. Viral infections in lung transplantation. J Thorac Dis. 2021 Nov;13(11):6673–94. doi: https://doi.org/10.21037/jtd-2021-24
  11. Zumla A, Al-Tawfiq JA, Enne VI, Kidd M, Drosten C, Breuer J, et al. Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections—needs, advances, and future prospects. Lancet Infect Dis. 2014 Nov;14(11):1123–35. doi: https://doi.org/10.1016/S1473-3099(14)70827-8
  12. Gunasekaran M, Bansal S, Ravichandran R, Sharma M, Perincheri S, Rodriguez F, et al. Respiratory viral infection in lung transplantation induces exosomes that trigger chronic rejection. J Heart Lung Transplant. 2020 Apr;39(4):379–88. doi: https://doi.org/10.1016/j.healun.2019.12.009
  13. Magnusson J, Westin J, Andersson LM, Lindh M, Brittain-Long R, Nordén R, et al. Viral respiratory tract infection during the first postoperative year is a risk factor for chronic rejection after lung transplantation. Transplant Direct. 2018 Jul;4(8):e370. doi: https://doi.org/10.1097/TXD.0000000000000808
  14. Schuurmans MM, Benden C, Inci I. Practical approach to early postoperative management of lung transplant recipients. Swiss Med Wkly. 2013 Apr;143(4):w13773. doi: https://doi.org/10.4414/smw.2013.13773
  15. Elm E Von, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Published online 2007:1453-1457.
  16. Allyn PR, Duffy EL, Humphries RM, Injean P, Weigt SS, Saggar R, et al. Graft loss and CLAD onset hastened by viral pneumonia after lung transplantation. Transplantation. 2016 Nov;100(11):2424–31. doi: https://doi.org/10.1097/TP.0000000000001346
  17. Fisher CE, Preiksaitis CM, Lease ED, Edelman J, Kirby KA, Leisenring WM, et al. Symptomatic respiratory virus infection and chronic lung allograft dysfunction. Clin Infect Dis. 2016 Feb;62(3):313–9. doi: https://doi.org/10.1093/cid/civ871
  18. Peghin M, Los-Arcos I, Hirsch HH, Codina G, Monforte V, Bravo C, et al. Community-acquired respiratory viruses as a risk factor for chronic lung allograft dysfunction. Clin Infect Dis. 2019 Sep;69(7):1192–7. doi: https://doi.org/10.1093/cid/ciy1047
  19. Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA, Schuster DP, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004 Jul;170(2):181–7. doi: https://doi.org/10.1164/rccm.200310-1359OC
  20. Dominguez SR, Travanty EA, Qian Z, Mason RJ. Human coronavirus HKU1 infection of primary human type II alveolar epithelial cells: cytopathic effects and innate immune response. PLoS One. 2013 Jul;8(7):e70129. doi: https://doi.org/10.1371/journal.pone.0070129
  21. Funk CJ, Wang J, Ito Y, Travanty EA, Voelker DR, Holmes KV, et al. Infection of human alveolar macrophages by human coronavirus strain 229E. J Gen Virol. 2012 Mar;93(Pt 3):494–503. doi: https://doi.org/10.1099/vir.0.038414-0
  22. Mitchell AB, Oliver BG, Glanville AR. Translational aspects of the human respiratory virome. Am J Respir Crit Care Med. 2016 Dec;194(12):1458–64. doi: https://doi.org/10.1164/rccm.201606-1278CI
  23. Li X, Luk KH. Human coronaviruses: general features. Reference Module in Biomedical Sciences. 2019 Mar 11:B978-0-12-801238-3.95704-0. doi: https://doi.org/10.1016/B978-0-12-801238-3.95704-0
  24. de Zwart A, Riezebos-Brilman A, Lunter G, Vonk J, Glanville AR, Gottlieb J, et al. Respiratory syncytial virus, human metapneumovirus, and parainfluenza virus infections in lung transplant recipients: a systematic review of outcomes and treatment strategies. Clin Infect Dis. 2022 Jul;74(12):2252–60. doi: https://doi.org/10.1093/cid/ciab969
  25. Jung EJ, Lee SK, Shin SH, Kim JS, Woo H, Cho EJ, et al. Comparison of nasal swabs, nasopharyngeal swabs, and saliva samples for the detection of SARS-CoV-2 and other respiratory virus infections. Ann Lab Med. 2023 Sep;43(5):434–42. doi: https://doi.org/10.3343/alm.2023.43.5.434